Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DGQU43
|
|||
| Drug Name |
Dostarlimab
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Endometrial cancer [ICD-11: 2C76; ICD-9: 182] | Approved | [1] | |
| Neoplasm [ICD-11: 2A00-2F9Z; ICD-10: C00-C96; ICD-9: 140-229] | Phase 3 | [2] | ||
| Breast cancer [ICD-11: 2C60-2C65; ICD-10: C50, C79.51] | Phase 2 | [3] | ||
| Multiple myeloma [ICD-11: 2A83; ICD-10: C90] | Phase 2 | [4] | ||
| Company |
AnaptysBio; GlaxoSmithKline
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Programmed cell death protein 1 (PD-1) | Target Info | Inhibitor | [5] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| T cell receptor signaling pathway | ||||
| Reactome | PD-1 signaling | |||
| WikiPathways | T-Cell Receptor and Co-stimulatory Signaling | |||
| Costimulation by the CD28 family | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. | |||
| REF 2 | ClinicalTrials.gov (NCT03981796) A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer (RUBY). U.S. National Institutes of Health. | |||
| REF 3 | ClinicalTrials.gov (NCT04837209) Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer (NADiR). U.S. National Institutes of Health. | |||
| REF 4 | ClinicalTrials.gov (NCT04126200) Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 5). U.S. National Institutes of Health. | |||
| REF 5 | Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer. Future Oncol. 2021 Mar;17(8):877-892. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.